Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a single site within the genome of a cell or subject, e.g., within the human genome. The disclosure provides fusion proteins of nucleic acid programmable DNA binding proteins (napDNAbp), e.g., Cas9 or variants thereof, and nucleic acid editing proteins such as cytidine deaminase domains (e.g., novel cytidine deaminases generated by ancestral sequence reconstruction), and adenosine deaminases that deaminate adenine in DNA. Aspects of the disclosure relate to fusion proteins (e.g., base editors) that have improved expression and/or localize efficiently to the nucleus. In some embodiments, base editors are codon optimized for expression in mammalian cells. In some embodiments, base editors include multiple nuclear localization sequences (e.g., bipartite NLSs), e.g., at least two NLSs. In some embodiments, methods for targeted nucleic acid editing are provided.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A method is provided for deterministically translocating through a nanopore a target polymer molecule of a nucleic acid polymer molecule or a protein polymer molecule. In the method, an enzyme clamp is reversibly bound to a plurality of sequential polymer subunits of the target polymer molecule. The target polymer molecule and the enzyme clamp are disposed at the nanopore. In the method, there is applied a pulse of force operative to deterministically advance the enzyme clamp along the target polymer molecule by no more than one polymer subunit. The pulse of force is then repeatedly applied to cause deterministic translocation of a sequential plurality of polymer subunits of the target polymer molecule through the nanopore.
Provided herein are methods of treating or ameliorating an immune-related adverse event associated with an immunotherapy or immune-modulating therapy in a subject with cancer, autoimmune disease or other condition requiring immune-modulating agents, the method comprising administering to the subject an agent that modulates the activity or expression of TIGIT.
Described herein are targeting moieties that can be capable of specifically targeting muscle cells and can include an n-mer motif. In some embodiments, the n-mer motif contains an RGD motif. Also described herein are vector systems, particles, polypeptides that can encode and/or contain one or more targeting moieties. Also described herein are methods of delivering a cargo to a cell, such as a muscle cell, using one or more of the targeting moieties described herein.
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A method of generating a plurality of different surface-decorated nanoparticles, decorated with different surface decoration, comprising: forming a plurality of microdroplets in a microfluidics device, each microdroplet comprising a nanoparticle and a respectively different macromolecule encoding a different surface decoration molecule; synthesising the surface decoration molecule, within each microdroplet, based on the macromolecule encoding the surface decoration molecule; conjugating the nanoparticle and the surface decoration molecule, within each microdroplet, to form surface decorated nanoparticles.
In some aspects, the present disclosure provides methods and compositions for isothermal low temperature amplification of target polynucleotides, and detection thereof.
C12Q 1/6818 - Tests d’hybridation caractérisés par les moyens de détection impliquant l’interaction de plusieurs marqueurs, p. ex. transfert d’énergie de résonance
Scents are perceived by the olfactory sensory neurons (OSNs) that line the upper nasal cavity. Each OSN expresses one odorant receptor, and these odorant receptors contact the scent molecules. Methods for determining which odorant receptor(s) are activated by a scent are lacking, making it difficult to replicate or improve scents. The technology as disclosed herein refers to methods relating to activating odor response genes found in olfactory sensory neurons after the neurons are exposed to at least one volatilized chemical compound.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
9.
SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME
Disclosed herein are methods, compositions, kits, and agents useful for inducing β cell maturation, and isolated populations of SC-β cells for use in various applications, such as cell therapy.
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
A61P 5/48 - Médicaments pour le traitement des troubles du système endocrinien des hormones pancréatiques
A61P 5/50 - Médicaments pour le traitement des troubles du système endocrinien des hormones pancréatiques pour augmenter ou potentialiser l'activité de l'insuline
The present invention features novel peripherally-restricted non-benzodiazipene analogs with reduced blood brain barrier permeability and methods of use thereof for reducing tactile dysfunction, social impairment, and anxiety in a subject diagnosed with Autism Spectrum Disorder, Rett syndrome, Phelan McDermid syndrome, or Fragile X syndrome, or for treating touch over-reactivity, pain, or mechanical allodynia.
Described herein are muscle-specific targeting moieties and compositions including the muscle specific targeting motifs. Also described herein are uses of the muscle-specific targeting motifs and compositions including the muscle specific targeting moieties. In some embodiments, the muscle-specific targeting moieties and compositions including the muscle specific targeting moieties can be used to direct delivery of a cargo to a muscle cell.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
12.
MANIPULATING AND ASSEMBLING MICRO- AND NANOSCALE OBJECTS WITH CAPILLARY FORCES
In some aspects, a device comprises a plurality of walls defining one or more channels; wherein the one or more channels have a cross-section in a plane perpendicular to a vertical axis of the device that changes along the vertical axis; and one or more floats sized to allow movement of the one or more floats within said one or more channels, wherein the one or more floats have a surface characteristic that is different from the surface characteristic of the walls such that, upon contact with a fluid, said walls and said floats form different contact angles and induce a repulsive capillary force between the walls and the one or more floats at a surface of the fluid.
Some aspects are generally related to articles comprising a lipid membrane (e.g., a vesicle) and a glycolipid at least partially embedded within the lipid membrane. In some cases, the glycolipid may be an agonist for a receptor and/or change at least one property of the article comprising the lipid membrane, which may make the article more suitable for associating with cells and/or being endocytosed by cells. In some cases, the lipid membranes may encapsulate entities such as small molecules, DNA and/or proteins, and thus the article may be suitable for drug delivery or other applications. Some aspects are related to articles comprising multiple glycolipids, which may impart various properties to the articles, for example, decreased zeta potentials and/or altered surface diffusion rates of lipids of the article. Still other aspects are generally directed to methods of making or using the articles, kits comprising the articles, or the like.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p. ex. génie protéique ou administration de médicaments
A61K 47/61 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique le composé organique macromoléculaire étant un polysaccharide ou l’un de ses dérivés
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
Parallel uses of microfluidic methods and devices for focusing and/or forming discontinuous sections of similar or dissimilar size in a fluid are described. In some aspects, the present invention relates generally to flow-focusing-type technology, and also to microfluidics, and more particularly parallel use of microfluidic systems arranged to control a dispersed phase within a dispersant, and the size, and size distribution, of a dispersed phase in a multi-phase fluid system, and systems for delivery of fluid components to multiple such devices.
B01F 33/3011 - Micromixeurs utilisant des moyens spécifiques pour disposer les écoulements à mélanger, p. ex. des géométries ou des dispositions de canaux utilisant un courant de gainage d'un fluide entourant un courant central d'un autre fluide, p. ex. pour réduire la section transversale du courant central ou pour produire des gouttelettes à partir du courant central
The present application provides compounds that are proteolysis targeting chimeras containing a celastrol-based ubiquitin ligase targeting moiety. Methods of using these compounds for treating various diseases, such as neurodegenerative diseases and cancer, are also provided.
C07J 63/00 - Stéroïdes ayant le squelette du cyclopenta[a]hydrophénanthrène modifié par expansion d'un seul cycle par un ou deux atomes
A61K 31/551 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole ayant deux atomes d'azote comme hétéro-atomes d'un cycle, p. ex. clozapine, dilazèpe
A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
The invention relates to a monomeric immunogen comprising one receptor binding domain of a Coronavirus spike protein, wherein the receptor binding domain includes at least 4 non-native. N-linked, glycosylation sites.
The present disclosure relates to methods aimed towards non-invasive targeted genomic and epigenomic sequencing of spatially-defined cellular or subcellular region. More particularly, the present disclosure relates to methods of using photoselection to achieve non-invasive targeted genomic and epigenomic sequencing of spatially-defined cellular or subcellular regions, via the use of light-activated probes.
Systems and methods for focused direction deposition of a micron or nanometer dimension polymeric fiber and materials of such fibers are described herein. Systems and methods employ one or more gas flows to entrain and deflect fibers produced by a rotary jet spinning system forming a focused fiber stream. Some embodiments enable control of alignment and distribution of the fibers with a relatively high fiber throughput.
Provided are isolated enhancer element sequences that regulate and restrict expression of a transgene, such as a therapeutic gene, to certain neuronal cell types and/or populations in the brain and CNS. Therapeutic virus vectors containing the cloned enhancer element sequences, particularly, recombinant adeno-associated virus (rAAV) vectors, and a transgene are described. The rAAV vectors, compositions and methods are useful for treating subjects afflicted with neuropsychiatric and neuropathological diseases, disorders and conditions and symptoms thereof. The vectors can be used to restore normal cellular function, e.g., by restoring expression of certain genes to the appropriate interneuron or neuron target cell populations, to address the root cause of the disease, e.g., by restoring the excitation-inhibition balance in the neuronal cell or cell population.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
The compositions and methods described herein are related to the identification of disease related genes, the expression of which involves a fraction of transcripts with a retained intron, comprising antisense oligonucleotides (ASO) compositions and methods that target genes which meet two criteria: the genes have a fraction of transcripts that retains an intron, and haploinsufficiency of the gene is associated with disease.
The present disclosure relates, at least in part, to methods and cells useful for promoting ubiquitination-independent protein degradation and for promoting protein stability using an engineered midnolin protein.
e.g.e.g., a muscle) in the human. Electronic circuits process these signals to decouple them based on frequency. A method using this system involves placing electrodes on human skin, generating and delivering a higher-frequency AC electrical signal, receiving and processing the higher-frequency electrical frequency and a lower-frequency bioelectrical signal to decouple the signals, to estimate impedance, and to calculate electrophysiological activity in the human.
222, wherein the redox-active species includes a substituent that forms an intramolecular hydrogen bond in the reduced state. The method is safe, scalable, and potentially inexpensive, as it utilizes non-volatile and potentially low-cost redox organic and inexpensive inorganic species and can operate at ambient temperature and pressure and can operate at high current densities.
H01M 10/0564 - Accumulateurs à électrolyte non aqueux caractérisés par les matériaux utilisés comme électrolytes, p. ex. électrolytes mixtes inorganiques/organiques l'électrolyte étant constitué uniquement de matériaux organiques
B01D 53/14 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par absorption
B01D 53/32 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par effets électriques autres que ceux prévus au groupe
24.
METHODS OF INHIBITING HSP90AB1 FOR THE TREATMENT OF DEGENERATIVE OCULAR DISEASES
A61K 31/711 - Acides désoxyribonucléiques naturels, c.-à-d. contenant uniquement des 2'-désoxyriboses liés à l'adénine, la guanine, la cytosine ou la thymine et ayant des liaisons 3'-5' phosphodiester
An optical component comprises a metasurface comprising nanoscale elements. The metasurface is configured to receive incident light and to generate optical outputs. The geometries and/or orientations of the nanoscale elements provide a first optical output upon receiving a polarized incident light with a first polarization, and provide a second optical output upon receiving a polarized incident light with a second polarization that is different from the first polarization.
G03H 1/02 - Procédés ou appareils holographiques utilisant la lumière, les infrarouges ou les ultraviolets pour obtenir des hologrammes ou pour en obtenir une imageLeurs détails spécifiques Détails
26.
Engineered liposome with cell membrane proteins to reduce melanosome transport
The present disclosure discloses an engineered liposome with cell membrane proteins to reduce melanosome transport and a preparation method thereof, and belongs to the technical field of cosmetics and biomedicine. The present disclosure provides the engineered liposome with cell membrane proteins to reduce melanosome transport and the preparation method thereof, which is easy to operate, requires no large-scale equipment, has few additives, and a preparation process is simple and environmentally friendly. The biomimetic liposome can significantly inhibit melanin transport. The fluorescence intensity of melanosomes in keratinocytes is found to decrease by 3.5-fold in a co-culture test of melanocytes and the keratinocytes, indicating that this biomimetic liposome is very effective in inhibiting accumulation of melanin in skin keratinocytes. These findings provide an effective strategy for reducing melanosome transfer to treat hyperpigmentation, while also introducing an alternate approach for regulating cellular communication of extracellular vesicles and organelles.
UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
Inventeur(s)
Knipe, David M.
Tran, Thao
Glorioso, Joseph C., Iii
Deluca, Neal A.
Abrégé
Provided herein is a herpes simplex virus 1 (HSV-1) recombinant virus, comprising one or more therapeutic payload sequences, wherein the genome comprises at least one alteration in each of a gene encoding infected cell polypeptides (ICP)0, a gene encoding ICP4, a gene encoding ICP22, a gene encoding ICP27 and a gene encoding ICP47, wherein the genome does not encode a functional ICP0, ICP4, ICP22, ICP27 and ICP47 protein, and wherein the genome comprises internal inverted repeat (joint) regions. Methods for using the same are also provided.
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
The present disclosure generally relates to the amplification of RNA, e.g., for MERFISH or other applications. One set of embodiments is generally directed to a method of synthesizing a nucleic acid. Some embodiments are drawn to systems and methods for in situ amplification of RNA, which may allow genome-scale imaging of RNAs, including short RNAs and RNA isoforms that are differentiated by short sequences. In some embodiments, RNA such as mRNA may be transcribed into cDNA using a reverse transcriptase. The reverse transcriptase can also be used to associate a promoter (for example, a T7 promotor)with the RNA, e.g., by using a template-switching oligonucleotide (TSO). The promotor sequence can then be used to amplify the RNA, e.g., using techniques such as in vitro transcription, which can be performed in situ. Having amplified or increased amounts of RNA in situ may be useful for certain applications, such as MERFISH, as the RNA is easier to detect. Other aspects are generally related to methods for using such techniques, kits involving such techniques, or the like.
Provided herein, in some embodiments, are methods, compositions and kits for controlling nucleation and assembly of molecular nanostructures, microstructures and macrostructures.
The present invention provides novel peripherally-restricted benzodiazepines with reduced blood brain barrier permeability and methods of use thereof for reducing tactile dysfunction, social impairment, and anxiety in a subject diagnosed with Autism Spectrum Disorder, Rett syndrome, Phelan McDermid syndrome, or Fragile X syndrome.
F25B 23/00 - Machines, installations ou systèmes ayant un seul principe de fonctionnement non compris dans les groupes , p. ex. utilisant l'effet de radiation sélective
C07C 211/15 - Composés contenant des groupes amino liés à un squelette carboné ayant des groupes amino liés à des atomes de carbone acycliques d'un squelette carboné saturé acyclique le squelette carboné étant substitué de plus par des atomes d'halogène ou par des groupes nitro ou nitroso
C07C 211/27 - Composés contenant des groupes amino liés à un squelette carboné ayant des groupes amino liés à des atomes de carbone acycliques d'un squelette carboné non saturé contenant au moins un cycle aromatique à six chaînons ayant des groupes amino reliés au cycle aromatique à six chaînons par l'intermédiaire de chaînes carbonées saturées
C07C 211/63 - Composés d'ammonium quaternaire ayant des atomes d'azote quaternisés liés à des atomes de carbone acycliques
C07C 215/08 - Composés contenant des groupes amino et hydroxy liés au même squelette carboné ayant des groupes hydroxy et des groupes amino liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant saturé et acyclique avec un seul groupe hydroxy et un seul groupe amino liés au squelette carboné
C07C 217/08 - Composés contenant des groupes amino et hydroxy éthérifiés liés au même squelette carboné ayant des groupes hydroxy éthérifiés et des groupes amino liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant acyclique et saturé ayant un seul groupe hydroxy éthérifié et un seul groupe amino liés au squelette carboné, qui n'est pas substitué par ailleurs l'atome d'oxygène du groupe hydroxy éthérifié étant lié de plus à un atome de carbone acyclique
C07C 229/08 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant acyclique et saturé ayant un seul groupe amino et un seul groupe carboxyle liés au squelette carboné l'atome d'azote du groupe amino étant lié de plus à des atomes d'hydrogène
32.
SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME
Disclosed herein are methods, compositions, kits, and agents useful for inducing β cell maturation, and isolated populations of SC-β cells for use in various applications, such as cell therapy.
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
A61P 5/48 - Médicaments pour le traitement des troubles du système endocrinien des hormones pancréatiques
A61P 5/50 - Médicaments pour le traitement des troubles du système endocrinien des hormones pancréatiques pour augmenter ou potentialiser l'activité de l'insuline
Exemplary embodiments provide systems, devices and methods for the fabrication of three-dimensional polymeric fibers having micron, submicron and nanometer dimensions, as well as methods of use of the polymeric fibers.
D01F 6/60 - Filaments, ou similaires, faits par l’homme, à un seul composant, formés de polymères synthétiquesLeur fabrication à partir de produits d'homopolycondensation à partir de polyamides
D01F 9/00 - Filaments, ou similaires, faits par l’homme, formés d’autres substancesLeur fabricationAppareils spécialement adaptés à la fabrication de filaments de carbone
A method of modulating some or all copies of a gene in a cell is provided including introducing into a cell one or more ribonucleic acid (RNA) sequences that comprise a portion that is complementary to all or a portion of each of the one or more target nucleic acid sequences, and a nucleic acid sequence that encodes a Cas protein and maintaining the cells under conditions in which the Cas protein is expressed and the Cas protein binds and modulates the one or more target nucleic acid sequences in the cell.
C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le ribosyle comme radical saccharide
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
Described in embodiments herein are thiol-ene polymeric compositions that exhibit photo-induced, reversible switching between a solid (e.g., elastomeric) state and a liquid (e.g., flowable) state. The thiol-ene polymeric compositions may comprise a vinyl oligomer comprising at least two vinyl groups, a thiol oligomer comprising at least two thiol groups, and a Type I photoinitiator. In some embodiments, the composition comprises an excess of thiol groups relative to vinyl groups (e.g., a ratio of thiol groups to vinyl groups in the composition is at least 3:1). Reversible switching between the solid state and the liquid state may be induced through exposure of the composition to electromagnetic radiation (e.g., ultraviolet (UV) radiation). In some cases, reversible switching may be induced by a relatively low amount of energy (e.g., about 1 J/cm2 or less).
F28D 20/02 - Appareils ou ensembles fonctionnels d'accumulation de chaleur en généralAppareils échangeurs de chaleur de régénération non couverts par les groupes ou utilisant la chaleur latente
C09K 5/06 - Substances qui subissent un changement d'état physique lors de leur utilisation le changement d'état se faisant par passage de l'état liquide à l'état solide, ou vice versa
C09K 5/14 - Substances solides, p. ex. pulvérulentes ou granuleuses
37.
NOCICEPTOR-SPECIFIC GENE REGULATORY ELEMENTS FOR THE TREATMENT OF PAIN
Aspects of the disclosure provide nucleic acids and compositions comprising gene regulatory elements (GREs) for specific expression in nociceptor cells. Other aspects of the disclosure relate to the use of vectors and compositions comprising the gene regulatory elements for treating or managing pain and other neurological diseases in a subject in need thereof.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
The present invention generally relates to droplets and/or emulsions, such as multiple emulsions. In some cases, the droplets and/or emulsions may be used in assays, and in certain embodiments, the droplet or emulsion may be hardened to form a gel. In some aspects, a heterogeneous assay can be performed using a gel. For example, a droplet may be hardened to form a gel, where the droplet contains a cell, DNA, or other suitable species. The gel may be exposed to a reactant, and the reactant may interact with the gel and/or with the cell, DNA, etc., in some fashion. For example, the reactant may diffuse through the gel, or the hardened particle may liquefy to form a liquid state, allowing the reactant to interact with the cell. As a specific example, DNA contained within a gel particle may be subjected to PCR (polymerase chain reaction) amplification, e.g., by using PCR primers able to bind to the gel as it forms. As the DNA is amplified using PCR, some of the DNA will be bound to the gel via the PCR primer. After the PCR reaction, unbound DNA may be removed from the gel, e.g., via diffusion of washing. Thus, a gel particle having bound DNA may be formed in one embodiment of the invention.
B01F 33/3011 - Micromixeurs utilisant des moyens spécifiques pour disposer les écoulements à mélanger, p. ex. des géométries ou des dispositions de canaux utilisant un courant de gainage d'un fluide entourant un courant central d'un autre fluide, p. ex. pour réduire la section transversale du courant central ou pour produire des gouttelettes à partir du courant central
B01F 33/302 - Micromixeurs les matières à mélanger s'écoulant sous forme de gouttelettes
B01F 101/23 - Mélange d'échantillons de laboratoire, p. ex. en vue d'analyser ou de tester les propriétés des matières
B01J 13/00 - Chimie des colloïdes, p. ex. production de substances colloïdales ou de leurs solutions, non prévue ailleursFabrication de microcapsules ou de microbilles
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
C12Q 1/6834 - Couplage enzymatique ou biochimique d’acides nucléiques à une phase solide
C12Q 1/6848 - Réactions d’amplification d’acides nucléiques caracterisées par les moyens d’empêcher la contamination ou d’augmenter la spécificité ou la sensibilité d’une réaction d’amplification
C12Q 1/686 - Réaction en chaine par polymérase [PCR]
G01N 15/10 - Recherche de particules individuelles
G01N 15/1404 - Manipulation du flux, p. ex. focalisation hydrodynamique
39.
SINGLE-STRANDED NUCLEIC ACID ANALOGS FOR USE AS MUTATION RESISTANT ANTIBACTERIAL TREATMENT
Described herein are compositions and methods of use related to oligonucleotides with modified nucleic acid backbones and conjugated to cell penetrating peptides that are complementary to 5'-GGTGGTGG-3' for the treatment of antibiotic-resistant bacterial infection.
40.
CREDIBLE EXCHANGE DESIGN VIA A VERIFIABLE SEQUENCING RULE
Systems and methods are provided for implementing a verifiable transaction block on an exchange, the verifiable transaction block including transactions (e.g., purchases and/or sales) that are to be executed on the exchange in accordance with an ordering of the transactions. The techniques provided include ordering, using a verifiable sequencing rule, the transactions of the set of transactions to obtain a transaction block of ordered transactions, and causing the execution of the ordered transactions. The transactions may indicate a purchase and/or a sale of at least one token of two or more tokens on a liquidity pool.
Provided herein are methods of rejuvenating, restoring cellular function to, decreasing the biological age of, decreasing the apparent chronological age of, and reprogramming cells, organs, and tissues, using chemical cocktails comprising two or more compounds described herein, or pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, or prodrugs thereof. Also provided herein are methods of treating a disease, methods of monitoring cellular aging, and pharmaceutical compositions and kits using two or more compounds described herein, or pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, or prodrugs thereof.
42.
Use of Metasurface Optical Components to Alter Incident Light
Metasurface optical components deposited on the surface of a substrate are used to alter incident light. The metasurface optical components comprise a pattern of silicon dielectric resonators that have nonperiodic gap distances between adjacent silicon dielectric resonators; and each silicon dielectric resonator is an elongated rectangular prism that has a width, a length, and a thickness. Incident light is directed to the metasurface optical components, wherein the gap distances, the widths, and the thicknesses are configured to scatter the incident light and impart a phase shift, ranging at least from 0 to 2π, on an outgoing light. Each dielectric resonator has a rectangular cross-section in a plane perpendicular to the substrate surface such that a first phase shift is imparted for a transverse-electric (TE) component of the incident light and a second phase shift is imparted for a transverse-magnetic (TM) component of the incident light.
H01Q 15/10 - Dispositifs de réfraction ou diffraction, p. ex. lentille, prisme concernant un réseau de discontinuité d'impédance tridimensionnel, p. ex. trous dans une surface conductrice ou disques conducteurs formant diélectrique artificiel
43.
MICROPOROUS PARTICLES TO ENHANCE GAS TRANSPORT IN MEMBRANES
This invention provides membranes including a polymer having dispersed therein a plurality of microporous particles. The membranes improve mass transport in polymer electrolyte fuel cells.
B01D 71/44 - Polymères obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, non prévus dans un seul des groupes
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (Suisse)
ETH ZURICH (Suisse)
PRESIDENT AND FELLOWS OF HARVARD COLLEGE (USA)
Inventeur(s)
Benea-Chelmus, Ileana-Cristina
Loncar, Marko
Faist, Jerome
Tomasino, Alessandro
Shams-Ansari, Amirhassan
Herter, Alexa
Lampert Almahmoud, Yazan
Abrégé
A terahertz device for detecting or emitting or for both detecting and emitting electromagnetic waves in the terahertz frequency range. The terahertz device comprises: a first waveguide branch and a second waveguide branch, the first and second waveguide branches being configured to allow optical signals to propagate through them, the first and second waveguide branches being nonlinear dielectric elements with a thickness of at most 500 micrometres; and an antenna arrangement comprising a set of antennas for capturing and/or emitting electromagnetic waves in the terahertz frequency range, the antennas being placed along at least one of the waveguide branches in an immediate vicinity of the respective waveguide branch and/or around the respective waveguide branch to at least partially enclose the respective waveguide branch in a respective antenna gap of the respective antenna.
The present disclosure provides compositions and methods for treating neurodevelopmental disorders, such as Rett syndrome and cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder.
A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
A61K 35/00 - Préparations médicinales contenant des substances ou leurs produits de réaction de constitution non déterminée
Described in several exemplary embodiments are compositions including a targeting moiety effective to target a central nervous system cell and formulations thereof. In certain embodiments, the targeting moiety is composed of one or more n-mer inserts, that can include one or more RGD motifs, and/or one or more P-motifs. Also described in certain example embodiments are vector systems configured to generate polypeptides containing the one or more targeting moieties. Also described herein are methods of generating a targeting moiety effective to target a central nervous system cell and using the compositions containing the targeting moieties described herein, such as to deliver a cargo to a subject and/or treat a central nervous system disease, disorder, or system thereof.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
The invention provides integrated Organ-on-Chip microphysiological systems representations of living Organs and support structures for such microphysiological systems.
C12M 3/06 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus avec des moyens de filtration, d'ultrafiltration, d'osmose inverse ou de dialyse
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
B01L 9/00 - Dispositifs de supportDispositifs de serrage
C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p. ex. par des compteurs de colonies
C12M 1/42 - Appareils pour le traitement de micro-organismes ou d'enzymes au moyen d'énergie électrique ou ondulatoire, p. ex. magnétisme, ondes sonores
C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
49.
REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA
The United States of America, as Represented by the Secretary, Department of Health and Human (USA)
President and Fellows of Harvard College (USA)
IIT Research Institute (USA)
Beth Israel Deaconess Medical Center, Inc. (USA)
Inventeur(s)
Solway, Julian
Dulin, Nickolai
Rosner, Marsha
Mutlu, Gokhan
Luci, Diane
Maloney, David
Park, Chan Young
Fredberg, Jeffrey
Mccormick, David
Krishnan, Ramaswamy
Abrégé
Disclosed herein is a class of molecules termed remodilins that inhibit serum response factor (SRF). By inhibiting SRF, a number of downstream pathways can be targeted. The remodilins can be used to treat glaucoma, inhibit tumor cell growth, inhibit tumor metastasis, inhibit hypoxia-induced response, and/or reduce cellular metabolism.
A61K 31/635 - Composés contenant des groupes para-N-benzènesulfonyl-N-, p. ex. sulfanilamide, p-nitrobenzènesulfonohydrazide contenant un hétérocycle, p. ex. sulfadiazine
A61K 31/63 - Composés contenant des groupes para-N-benzènesulfonyl-N-, p. ex. sulfanilamide, p-nitrobenzènesulfonohydrazide
A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
C07C 311/16 - Sulfonamides ayant des atomes de soufre de groupes sulfonamide liés à des atomes de carbone de cycles aromatiques à six chaînons ayant l'atome d'azote d'au moins un des groupes sulfonamide lié à des atomes d'hydrogène ou à un atome de carbone acyclique
C07C 311/21 - Sulfonamides ayant des atomes de soufre de groupes sulfonamide liés à des atomes de carbone de cycles aromatiques à six chaînons ayant l'atome d'azote d'au moins un des groupes sulfonamide lié à un atome de carbone d'un cycle aromatique à six chaînons
C07D 211/34 - Composés hétérocycliques contenant des cycles pyridiques hydrogénés, non condensés avec d'autres cycles avec uniquement des atomes d'hydrogène et de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle avec des radicaux hydrocarbonés substitués liés aux atomes de carbone du cycle avec des radicaux hydrocarbonés, substitués par des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
C07D 241/04 - Composés hétérocycliques contenant des cycles diazine-1,4 ou diazine-1,4 hydrogéné non condensés avec d'autres cycles ne comportant pas de liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques
C07D 265/30 - Oxazines-1, 4Oxazines-1, 4 hydrogénées non condensées avec d'autres cycles
C07D 277/52 - Atomes d'azote liés à des hétéro-atomes à des atomes de soufre, p. ex. sulfamides
C07D 279/12 - Thiazines-1, 4Thiazines-1, 4 hydrogénées non condensés avec d'autres cycles
C07D 295/13 - Composés hétérocycliques contenant des cycles polyméthylène imine d'au moins cinq chaînons, des cycles aza-3 bicyclo [3.2.2] nonane, piperazine, morpholine ou thiomorpholine, ne comportant que des atomes d'hydrogène liés directement aux atomes de carbone du cycle avec des radicaux hydrocarbonés substitués liés aux atomes d'azote du cycle substitués par des atomes d'azote liés par des liaisons simples ou doubles avec les atomes d'azote du cycle et les atomes d'azote substituants liés à la même chaîne carbonée, qui n'est pas interrompue par des cycles carbocycliques à une chaîne acyclique saturée
C07D 309/14 - Atomes d'azote ne faisant pas partie d'un radical nitro
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A textile actuator worn by a user comprises a textile envelope that defines a chamber made fluid-impermeable by a fluid-impermeable bladder contained in the textile envelope and/or a fluid-impermeable structure incorporated into the textile envelope. The textile envelope has a pre-determined geometry that produces an equilibrium state at a non-180°-angle displacement and that stops further displacement upon pressurization of the chamber and prevents over-extension of the joint. A fluid is delivered into or out of the chamber to displace the textile envelope primarily by transitioning from an uninflated state to the pre-determined geometry due to displacement of the textile envelope rather than via stretching or contraction of the textile envelope. When actuated, the textile actuator (a) displaces a body segment of the user and/or (b) supports and holds the body segment of the user in place.
F15B 15/10 - Dispositifs actionnés par fluides pour déplacer un organe d'une position à une autreTransmission associée à ces dispositifs caractérisés par la structure de l'ensemble moteur le moteur étant du type à diaphragme
Disclosed herein are genes which are differentially expressed in venule endothelial cells (V-ECs) compared to non-venule endothelial cells (NV-ECs), and methods and compositions relating to those genes. In particular, described herein are methods of reducing the venuleness of endothelial cells (ECs) for treating inflammatory diseases, and methods of increasing the venuleness of ECs for treating cancers.
C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
The present disclosure provides new ion channel binding compounds and uses thereof. Further provided are methods of treating diseases and disorders including painful conditions and neurological diseases.
C07C 255/36 - Nitriles d'acides carboxyliques ayant des groupes cyano liés à des atomes de carbone acycliques ayant des groupes cyano liés à des atomes de carbone acycliques d'un squelette carboné contenant au moins un cycle aromatique à six chaînons le squelette carboné étant substitué de plus par des groupes hydroxy
C07C 39/27 - Les atomes d'halogène étant tous liés au cycle
53.
MULTIPLE EMULSIONS CREATED USING JETTING AND OTHER TECHNIQUES
The present invention generally relates to emulsions, and more particularly, to multiple emulsions. In one aspect, multiple emulsions are formed by urging a fluid into a channel, e.g., by causing the fluid to enter the channel as a “jet.” Side channels can be used to encapsulate the fluid with a surrounding fluid. In some cases, multiple fluids may flow through a channel collinearly before multiple emulsion droplets are formed. The fluidic channels may also, in certain embodiments, include varying degrees of hydrophilicity or hydrophobicity. As examples, the fluidic channel may be relatively hydrophilic upstream of an intersection (or other region within the channel) and relatively hydrophobic downstream of the intersection, or vice versa. In some cases, the average cross-sectional dimension may change, e.g., at an intersection. For instance, the average cross-sectional dimension may increase at the intersection. Surprisingly, a relatively small increase in dimension, in combination with a change in hydrophilicity of the fluidic channel, may delay droplet formation of a stream of collinearly-flowing multiple fluids under certain flow conditions; accordingly, the point at which multiple emulsion droplets are formed can be readily controlled within the fluidic channel. In some cases, the multiple droplet may be formed from the collinear flow of fluids at (or near) a single location within the fluidic channel. In addition, unexpectedly, systems such as those described herein may be used to encapsulate fluids in single or multiple emulsions that are difficult or impossible to encapsulate using other techniques, such as fluids with low surface tension, viscous fluids, or viscoelastic fluids. Other aspects of the invention are generally directed to methods of making and using such systems, kits involving such systems, emulsions created using such systems, or the like.
B01F 33/3011 - Micromixeurs utilisant des moyens spécifiques pour disposer les écoulements à mélanger, p. ex. des géométries ou des dispositions de canaux utilisant un courant de gainage d'un fluide entourant un courant central d'un autre fluide, p. ex. pour réduire la section transversale du courant central ou pour produire des gouttelettes à partir du courant central
54.
ANTI-PMEPA-1 ANTIBODIES OR ANTIGEN BINDING FRAGMENTS THEREOF, COMPOSITIONS, AND USES THEREOF
The technology described herein is directed to antibody or antigen binding fragments thereof, e.g., nanobody, to PMEPA-1 overexpressed in tumor vascular endothelial cells. The antibody or antigen binding fragments to PMEPA-1 can be used to target an agent, for example, that induces cell death, for example, immunogenic or non-immunogenic cancer cell death, and in methods of treating cancer.
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
Described in several exemplary embodiments are compositions including a targeting moiety effective to target a central nervous system cell and formulations thereof. In certain embodiments, the targeting moiety is composed of one or more n-mer inserts, that can include one or more RGD motifs, and/or one or more P-motifs. Also described in certain example embodiments are vector systems configured to generate polypeptides containing the one or more targeting moieties. Also described herein are methods of generating a targeting moiety effective to target a central nervous system cell and using the compositions containing the targeting moieties described herein, such as to deliver a cargo to a subject and/or treat a central nervous system disease, disorder, or system thereof.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
56.
ENGINEERED VIRAL LIKE PARTICLES (EVLPS) FOR THE SELECTIVE TRANSDUCTION OF TARGET CELLS
The present disclosure provides compositions and methods for the selective transduction and genome editing of human cells (e.g., hematopoietic stem and progenitors cells, HSPCs) using engineered viral like particles (eVLPs). Aspects of the disclosure provide eVLP compositions comprising fusion proteins comprising a targeting moiety. In some embodiments, the fusion proteins comprise a cytokine conjugated to a transmembrane protein and/or an envelope glycoprotein. In other embodiments, the fusion proteins comprise a targeting moiety domain, a stalk protein domain, a transmembrane and/or envelope glycoprotein domain. Targeted-eVLP architectures comprising various targeting domains, stalk domains, transmembrane domains, and envelope glycoproteins are also provided herein. Other aspects of the disclosure provide eVLP compositions comprising envelope glycoproteins comprising non-natural sugars and methods of conjugating said eVLPs to various targeting moieties using bio-orthogonal click chemistry. Polynucleotides, vectors, cells, and kits useful for producing the articles, and performing the methods, described herein are also provided.
The technology described herein is directed to targeting molecules that bind to one or more transmembrane molecules expressed in tumor vascular endothelial cells and that are capable of targeting an agent that induces cell death, for example, immunogenic or non-immunogenic cancer cell death. In another aspect, described herein are methods of treating a subject having cancer comprising administering said targeting molecules and agents, and, in certain embodiments, enhancing the immunogenic response to the cancer, for example, by enhancing intratumoral infiltration of T cells.
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
59.
METHODS FOR NEOPLASIA DETECTION FROM CELL FREE DNA
The disclosure features compositions and methods that are useful for determining the fraction of tumor-derived DNA (tumor fraction; TF) in cell free DNA (cfDNA). The methods involve calculating the fraction of tumor-derived DNA in the cfDNA using a combination of copy number alteration data and fragment length distribution data.
The present disclosure generally relates to microscopy, including confocal microscopy. In some cases, techniques such as MERFISH can be used to determine nucleic acids within a sample, with images acquired using confocal microscopy. In some cases, the nucleic acids may be determined in 3 dimensions. In some cases, relatively thick samples, e.g., at least 100 micrometers thick, may be determined. In some embodiments, deep learning or other machine learning techniques may be used to enhance the image quality and/or speed up the confocal imaging process.
Immunogenic compositions comprising one or more peptides, wherein the one or more peptides: are capable of binding to Major Histocompatibility Complex (MHC) class II, and are derived from one or more translation products of SARS-CoV-2. Also provided include methods of treating and preventing diseases using the immunogenic compositions.
62.
GENETICALLY ENCODED VOLTAGE INDICATORS AND USES THEREOF
Provided herein are genetically encoded voltage indicator (GEVI) variants (e.g., QuasArba, QuasArbb) of Archaerhodopsin 3 useful for applications, such as optical measurement of membrane potential. Described herein are also polynucleotides encoding the variants, nucleic acid constructs, vectors (e.g., expression vectors), cells comprising the polynucleotides, nucleic acid constructs, and vectors, and cells comprising the polypeptides; and methods of using the variants.
C07K 14/215 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant d'Halobacteriaceae (F)
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
G01N 33/566 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet utilisant un support spécifique ou des protéines réceptrices comme réactifs pour la formation de liaisons par ligand
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
A tape for collecting tissue samples in a manner compatible with imaging in a transmission electron microscopy (TEM) system, includes a tape substrate having two side walls forming a trough. The trough is defined by a bottom surface of the tape substrate and internal surfaces of the side walls, with an open side therebetween. A support film is attached to a top surface of the tape substrate, and a plurality of apertures is spaced at predetermined locations along the length of the tape substrate, each aperture being covered by the support film. The tape includes a stacked configuration in which the tape substrate is wound in layers, the bottom surfaces of the side walls in one layer being in contact with the support film in an immediately adjacent layer. The apertures in the second layer are aligned within the trough of the first layer, between the side walls.
G01N 1/36 - Enrobage ou montage analogue d'échantillons
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes Manipulation de matériaux à cet effet
H01J 37/20 - Moyens de support ou de mise en position de l'objet ou du matériauMoyens de réglage de diaphragmes ou de lentilles associées au support
64.
Nanopore-matched protein shuttle for molecular characterization and methodology for data analysis thereof
Systems and methods are provided for characterizing shuttle capture events in a nanopore sensor. The method first collects time-dependent current blockage signatures for at least one bias voltage. The method then identifies each signature as corresponding to a permanent or transient event. The method then generates a protein dynamics landscape (PDL) for the transient event signatures. The PDL comprises a set of histograms of nanopore current data and characterizes current through the nanopore during shuttle capture events. The method can then comprise identifying an entrance level blockage value based on the permanent event signatures. Permanent event captures can be determined by time duration which is larger than a certain threshold time value. Applying a voltage between the fluidic chambers above a threshold voltage level can be used to control that the vast majority of events are permanent.
Computer-implemented system and method are disclosed herein for fine tuning a neural network model. The method includes seeking, in a loss landscape, a nonlinear path with a loss barrier from a loss function associated with a first neural network model. The method further includes altering, in response to said seeking, one or more mechanisms of the first neural network model to induce a second neural network model.
The invention provides methods, devices, and systems for applications requiring control of heat transfer, such as thermal management of electronic device, cooling, heating, and energy storage. The invention provides a method of controlling the flow of heat by providing a device including a spin crossover material having a low spin state and a high spin state, where the low spin state has higher thermal conductivity than the high spin state, and where the spin crossover material undergoes spin crossover between the low and high spin states in response to a stimulus.
Provided herein are compositions, including pharmaceutical compositions, comprising a binder, linker, and a radioactive isotope, and optionally a masking moiety. The compositions can also comprise a first binder connected to a second binder via a first linker, or a binder connected to a payload via a first linker. In some embodiments, the binder or first binder may specifically bind to a protein (e.g., PMEPA-1) expressed on an endothelial cell. Also provided herein are cells comprising a binder that binds to a protein expressed on an endothelial cell. Also provided herein are engineered immune cells comprising a polynucleotide that encodes a chimeric antigen receptor (CAR) that binds to a protein expressed on an endothelial cell. Also provided herein are methods for using these compositions for selective delivery to cells, treating diseases and disorders, and imaging. In some embodiments, the method comprises administering to the subject an effective amount of the composition disclosed herein.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
68.
RECONFIGURABLE ARCHITECTURE FOR PARALLEL QUANTUM OPERATIONS IN NEUTRAL ATOM ARRAYS
Quantum processors are provided. A first plurality of neutral atoms is provided in an active zone, each in a respective optical trap of a first array. A first logical qubit is encoded into the first plurality of neutral atoms by first and second lasers. The first plurality of neutral atoms is illuminated while in the active zone by at least the first or second laser, thereby applying a gate to the first logical qubit. The first plurality of neutral atoms is adiabatically moved from the active zone to a readout zone, each to a respective optical trap of a second array. The first plurality of neutral atoms is illuminated while in the readout zone by a third laser. An image of the first plurality of neutral atoms is captures while in the readout zone, thereby determining the state of the first logical qubit.
G06N 10/20 - Modèles d’informatique quantique, p. ex. circuits quantiques ou ordinateurs quantiques universels
G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p. ex. couplage ou commande de qubit
G06N 10/70 - Correction, détection ou prévention d’erreur quantique, p. ex. codes de surface ou distillation d’état magique
69.
SYSTEMS AND METHODS OF SCALABLE CONVEX RECURRENT NEURAL NETWORK TRAINING FOR INTERPRETING BRAIN DYNAMICS
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Dinc, Fatih
Tanaka, Hidenori
Abrégé
Computer-implemented methods and systems for training a neural network to interpret neural dynamics, the method comprising obtaining functional connectivity between brain regions and artificial neurons simulated by the neural network, capturing neural activities between biological neurons, processing the captured neural activities to obtain training data for the neural network, and constructing the neural network using the training data, to reproduce neural dynamics between the artificial neurons.
e.ge.g., improved editing efficiency when used in the context of a prime editor). Fusion proteins, including for example prime editors, comprising the reverse transcriptase variants and Cas9 variants described herein are also provided by the present disclosure. The present disclosure also provides polynucleotides encoding the reverse transcriptase variants, Cas9 variants, and prime editors provided herein, as well as vectors comprising such polynucleotides. Pharmaceutical compositions and cells comprising the reverse transcriptase variants, Cas9 variants, and prime editors described herein are also provided by the present disclosure. The present disclosure also provides methods and uses involving the reverse transcriptase variants, Cas9 variants, and prime editors described herein.
Provided herein are polymeric particles and compositions (i.e., “backpacks”) that can adhere to cells and provide delivery of payload agents to those cells, and/or direct therapeutic activity of those cells.
A61K 49/18 - Préparations de contraste pour la résonance magnétique nucléaire [RMN]Préparations de contraste pour l'imagerie par résonance magnétique [IRM] caractérisées par un aspect physique particulier, p. ex. émulsions, microcapsules, liposomes
Provided herein, in some embodiments, are recombinant viral genomes comprising an inhibitory oligonucleotide that reduces inflammation for use, for example, in gene therapy.
The invention relates to synthetic methods for the functionalization of an anthraquinone molecule comprising at least one amino-or carbonyl-substituent. In some aspects of the invention, the synthetic functionalization of the anthraquinone molecule takes place electrochemically within a divided electrolytic cell, e.g., the cell of a redox flow battery.
09 - Appareils et instruments scientifiques et électriques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Downloadable application software for use in connection with tracking personal progress, wellness goals, time management, and life goals Provision of non-downloadable computer software via a website to track personal progress, wellness goals, time management and life goals
41 - Éducation, divertissements, activités sportives et culturelles
Produits et services
Conducting of in-person educational forums in the field of politics, general public policy, public administration, international development, political economic policy, health policy, social policy, economics, sociology, leadership and ethics; Educational services in the nature of courses at the university level; provision of educational training and courses in the field of international affairs, international diplomacy, environmental and resource issues, and science and technology policy; Educational services, namely, providing courses of instruction and training at the university level in the fields of government, politics, public policy, and related subjects
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Platform as a service (PAAS) featuring computer software
platforms for providing users with access to media content
in the field of business, management, and entrepreneurship;
providing temporary use of on-line non-downloadable software
and applications using artificial intelligence (AI) for
mentoring and tutoring the user in the field of business,
management, and entrepreneurship; providing
subscription-based temporary use of non-downloadable
cloud-based software for providing users with access to
media content in the field of business, management, and
entrepreneurship; computer services, namely, creating an
on-line community for registered users to participate in
discussions, get feedback from their peers, form virtual
communities, and engage in social networking services in the
field business, management, and entrepreneurship.
Provided herein are methods of treating or preventing cancer in a subject, the method comprising administering to the subject a compound having the structure of Formula I, Formula II, or Formula III, or a pharmaceutically acceptable salt thereof.
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
A61K 31/4355 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'oxygène comme hétéro-atome du cycle
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
A61K 31/4375 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. quinolizines, naphtyridines, berbérine, vincamine
A61K 31/4985 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes hétérocycliques
A61K 31/5025 - PyridazinesPyridazines hydrogénées condensées en ortho ou en péri avec des systèmes hétérocycliques
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/53 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec trois azote comme seuls hétéro-atomes d'un cycle, p. ex. chlorazanil, mélamine
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
The present disclosure generally provides microgels, e.g., microgel scaffolds, and method for modulating the immune system of a subject. The compositions and methods described herein are useful for enhancing the reconstitution of the immune system of a subject, for example, after allogeneic hematopoietic stem cell transplantation (HSCT).
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
Compositions and methods useful for treating a number of human disorders including, but not limited to, cancer, cardiovascular disease, obesity, and metabolic disorders are provided. For example, the disclosure features compositions and methods for modulating the hydroxylation of ACC2 by PHD3 in vitro or in vivo. Also provided are methods for monitoring and/or detecting the expression of PHD3 and/or levels of ACC2 hydroxylation, which are useful for, inter alia, determining whether a cancer cell is sensitive to glycolytic pathway inhibitors or inhibitors of fatty acid metabolism.
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
A61K 31/336 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à trois chaînons, p. ex. oxirane, fumagilline
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p. ex. pipérazine
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
82.
BIOENGINEERING AND MACHINE LEARNING FRAMEWORK FOR COMPLEX TISSUE DEVELOPMENT
Provided herein is a bioengineering and machine learning framework for complex tissue development, which can be implemented for the identification and/or assessment of gene and/or drug therapies.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
The invention provides methods for inducing, enhancing or increasing satellite cell proliferation, and an assay for screening for a candidate compound for inducing, enhancing or increasing satellite cell proliferation. Also provided are methods for repairing or regenerating a damaged muscle tissue of a subject.
A61K 31/553 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole ayant au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p. ex. loxapine, staurosporine
A61K 31/403 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des carbocycles, p. ex. carbazole
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
Disclosed herein is a photonic material for reducing transmission of ultraviolet light. The photonic material has spherical scatterers in a matrix material. The spherical scatterers have an amorphous arrangement in the matrix material and are configured to scatter ultraviolet light traveling in the matrix material. The amorphous arrangement of the spherical scatterers causes multiple scattering of the ultraviolet light. Absorbing material is disposed within the matrix material or the spherical scatterers and absorbs the ultraviolet light traveling in the matrix material.
Disclosed herein are methods, differentiation protocols and compositions useful for inducing a cell maturation, and isolated populations of SC-α cells for use in various applications, such as cell therapy.
The present disclosure provides compounds of Formula (I) and (II), which may be ROCK2 inhibitors. The present disclosure also provides pharmaceutical compositions and kits comprising the compounds, and methods of treating or preventing diseases and disorders associated with ROCK2 (e.g., fibrotic disease, autoimmune disease, inflammatory-fibrotic condition, inflammatory condition, edema, ophthalmic disease, cardiovascular disease, central nervous system disorder, cancer) by administering to a subject in need thereof the compounds or pharmaceutical compositions.
The present disclosure provides compounds of Formula (I) and (II), which may be ROCK2 inhibitors. The present disclosure also provides pharmaceutical compositions and kits comprising the compounds, and methods of treating or preventing diseases and disorders associated with ROCK2 (e.g., fibrotic disease, autoimmune disease, inflammatory-fibrotic condition, inflammatory condition, edema, ophthalmic disease, cardiovascular disease, central nervous system disorder, cancer) by administering to a subject in need thereof the compounds or pharmaceutical compositions.
C07D 403/14 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
A61K 31/416 - 1,2-Diazoles condensés avec des systèmes carbocycliques, p. ex. indazole
A61K 31/4178 - 1,3-Diazoles non condensés et contenant d'autres hétérocycles, p. ex. pilocarpine, nitrofurantoïne
A61K 31/422 - Oxazoles non condensés et contenant d'autres hétérocycles
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 31/497 - Pyrazines non condensées contenant d'autres hétérocycles
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
Disclosed herein are universal donor stem cells and related methods of their use and production. The universal donor stem cells disclosed herein are useful for overcoming the immune rejection in cell-based transplantation therapies. In certain embodiments, the universal donor stem cells disclosed herein do not express one or more MHC-I and MHC-II human leukocyte antigens. Similarly, in certain embodiments, the universal donor stem cells disclosed herein do not express one or more human leukocyte antigens (e.g., HLA-A, HLA-B and/or HLA-C) corresponding to MHC-I and MHC-II human leukocyte antigens, thereby rendering such cells hypoimmunogenic.
Disclosed herein are universal donor stem cells and related methods of their use and production. The universal donor stem cells disclosed herein are useful for overcoming the immune rejection in cell-based transplantation therapies. In certain embodiments, the universal donor stem cells disclosed herein do not express one or more MHC-I and MHC-II human leukocyte antigens. Similarly, in certain embodiments, the universal donor stem cells disclosed herein do not express one or more human leukocyte antigens (e.g., HLA-A, HLA-B and/or HLA-C) corresponding to MHC-I and MHC-II human leukocyte antigens, thereby rendering such cells hypoimmunogenic.
A device for performing an assay includes a housing, an elongated member, and a vent. The housing has a first end and a second end. The housing defines a first opening at the first end, a first chamber, and a second chamber. The first chamber is fluidly connected to (i) the second chamber, and (ii) an exterior of the housing via the first opening. The elongated member is configured to be received through the first opening such that the elongated member is least partially disposed within the first chamber. The vent is configured to aid in controlling flow of a fluid from the first chamber of the housing to the second chamber of the housing.
A method of printing patterned tissue includes flowing a bioink comprising cells and a biological cargo through a nozzle moving relative to a substrate and exposing selected voxels of the bioink to a pulsed electric field as the bioink flows through the nozzle. Consequently, a portion or all of the cells in each of the selected voxels undergoes electroporation and transfection with the biological cargo. A cell-laden filament comprising the bioink and including the selected voxels is continuously extruded from an outlet of the nozzle, and, as the nozzle moves relative to the substrate, the cell-laden filament is deposited in a predetermined pattern on the substrate. Thus, a tissue having spatial patterns of gene expression may be printed.
A61L 27/54 - Matériaux biologiquement actifs, p. ex. substances thérapeutiques
B41J 2/005 - Machines à écrire ou mécanismes d'impression sélective caractérisés par le procédé d'impression ou de marquage pour lequel ils sont conçus caractérisés par la mise en contact sélective d'un liquide ou de particules avec un matériau d'impression
A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
The present disclosure provides for systems and methods for reversible storage of hydrogen using an electrolyte, including redox active molecules. Unlike other methods that employ a temperature or pressure swing, the present invention demonstrates hydrogen storage and release utilizing a voltage swing.
The invention provides methods of electrochemically rebalancing electrochemical systems such as flow batteries and electrochemical CO2 capture systems. Electrochemical imbalances due to reaction with molecular oxygen can lead to capacity loss. The loss of capacity may be mitigated by electrically oxidizing the excess hydroxide ions to produce gaseous O2, which can be removed by de-gassing methods.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
THE BROAD INSTITUTE, INC. (USA)
PRESIDENT AND FELLOWS OF HARVARD COLLEGE (USA)
Inventeur(s)
Quinn, Peter M. J.
Lopes Da Costa, Bruna
Tsang, Stephen H.
Liu, David R.
Abrégé
The present disclosure provides systems, methods, and compositions for modifying the crumbs homologue-1 gene. Particularly the present disclosure provides systems, methods, and compositions for prime editing insertion or correction of mutations in the crumbs homologue-1 gene.
A replacement heart valve device is disclosed. In some embodiments, the device includes a frame coupled to one or more leaflets that are moveable between open and closed configurations. In some embodiments, the frame comprises at least two frame sections that join at a pair of commissural posts. In some embodiments, the device may be geometrically accommodating to adapt to different vasculature shapes and sizes and/or to be able to change size while implanted within a growing patient.
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
PRESIDENT AND FELLOWS OF HARVARD COLLEGE (USA)
Inventeur(s)
Rodriguez, Raphaël
Solier, Stéphanie
Müller, Sébastian
Cañeque, Teresa Tatiana
Ubellacker, Jessalyn
Abrégé
The invention relates to a pharmaceutical composition for use in a method for the treatment of cancer and/or immune deficiency diseases and/or infectious diseases, comprising a metal ion and optionally hyaluronate (HA) or a hyaluronate conjugate, wherein said method comprises the intralymphatic administration of the pharmaceutical composition to a subject. The invention also relates to a pharmaceutical combination for use in a method for the treatment of cancer, the pharmaceutical combination comprising: (i) at least one metal ion, preferably selected in the group consisting of iron (Fe), copper (Cu), manganese (Mn), calcium (Ca), magnesium (Mg),zinc (Zn), and mixtures thereof; and (ii) hyaluronate (HA) or a hyaluronate conjugate, wherein said method comprises the simultaneous, separate or sequential administration of (i) and (ii) directly into the lymphatic system, preferably into a lymph node or a lymph vessel.
The embodiments disclosed herein utilized RNA targeting effectors to provide a robust CRISPR-based diagnostic with attomolar sensitivity. Embodiments disclosed herein can detect both DNA and RNA with comparable levels of sensitivity and can differentiate targets from non-targets based on single base pair differences. Moreover, the embodiments disclosed herein can be prepared in freeze-dried format for convenient distribution and point-of-care (POC) applications. Such embodiments are useful in multiple scenarios in human health including, for example, viral detection, bacterial strain typing, sensitive genotyping, and detection of disease-associated cell free DNA.
Embodiments of various aspects described herein relate to methods, kits, and cell culture media for generation of podocytes from pluripotent stem (PS) cells, as well as cells produced by the same, and methods of use.
The present invention is directed to methods for the treatment or prevention of oxidative stress in a cell, e.g., photoreceptor cell, and methods for the treatment and prevention of disorders associated therewith by the administration of an agent, e.g., a nucleic acid molecule, which increases the expression and/or activity of an antioxidant defense protein.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61K 31/7115 - Acides nucléiques ou oligonucléotides ayant des bases modifiées, c.-à-d. autres que l'adénine, la guanine, la cytosine, l'uracile ou la thymine
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A structural mesh for a tissue construct may comprise a mesh casing shaped to partially or fully enclose a tissue construct. The mesh casing may comprise a mesh material having a stiffness sufficient for the mesh casing to provide structural support while the tissue construct sustains internal pressure from blood circulation. Pores in the mesh casing may allow for transport of oxygen and nutrients between the tissue construct and a surrounding environment.
100.
DIAGNOSTIC SYSTEM FOR MONITORING OF MOVEMENT DISORDERS
Disclosed embodiments may include a diagnostic system including at least one sensor configured to measure signals associated with a change in skin curvature on a target limb of a subject and a processor configured to determine one or more disease state metrics based at least in part on a signal measured by the at least one sensor during one or more motion cycles. A method of determining disease state metrics is also described.
A61B 5/11 - Mesure du mouvement du corps entier ou de parties de celui-ci, p. ex. tremblement de la tête ou des mains ou mobilité d'un membre
A61B 5/256 - Électrodes portables, p. ex. avec des sangles ou des bandes
G16H 40/63 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement local
G16H 40/67 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement à distance
